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Abstract
Background: There are currently no effective therapeutic methods for locally recurrent, metastatic, or progressive
radioactive iodine (RAI)-refractory differentiated thyroid cancer. However, multitargeted tyrosine kinase inhibitors
(TKIs) such as lenvatinib or sorafenib have been approved for patients with RAI-refractory differentiated thyroid
cancer as a second targeted therapy, and these agents can prolong patient survival. However, several cases have
been reported that TKIs have caused fatal complications such as fistula formation or bleeding.
Case presentation: We report a case of a 53-year-old woman, who underwent repeated neck dissections and RAI
therapy after total thyroidectomy in an outside hospital. Pathology revealed a papillary carcinoma of the tall cell
variant. Locoregional recurrence was not under control; therefore, she visited our hospital. Although surgery was
performed for locoregional recurrences three times in our hospital, they were not under control and distant
metastases were found in the lung and bone a year later. Therefore, although sorafenib was initiated, the
locoregional recurrence progressed 6 months later and computed tomography (CT) showed a 7-cm mass in the
right subclavicular lesion. Lenvatinib was started at a dose of 24 mg daily. However, although tumor was rapidly
reduced, an ulcer occurred in the right subclavicular lesion and was gradually increasing in size. The pulsation of
subclavicular artery was found in the deep portion of the ulcer. Therefore, a pectoralis major myocutaneous flap
was transplanted to cover the ulcer. Lenvatinib was an antiangiogetic TKI; therefore, it was preoperatively
discontinued for 8 days and postoperatively for 12 days. The postoperative course was uneventful.
Conclusions: Fistula formation or bleeding is known to be a severe side effect of antiangiogenic TKIs such as
lenvatinib or sorafenib. There is a possibility that severe complications can occur when initiating TKIs in patients
whose tumor has invaded into the skin, vessels, trachea, esophagus, and other areas. Therefore, it is necessary to
use antiangiogenic TKIs very carefully. It is important to determine the appropriate time to start TKIs; however, there
is no established protocol for this, and it is a problem that needs urgent attention.
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Background
Thyroid cancer is a common malignant tumor that has a
good prognosis. However, we sometimes encounter
patients with locally recurrent, metastatic, or progressive
radioactive iodine (RAI)-refractory differentiated thyroid
cancer. Treatment options are limited in these cases. A
multitargeted tyrosine kinase inhibitor (TKI) such as
lenvatinib or sorafenib was recently approved as a
second targeted therapy for these cases. Treatment of
advanced forms of endocrine cancer which are not
responsive to cytotoxic chemotherapies is challenging,
and use of TKIs is gaining a growing role in this clinical
context [1].
Lenvatinib or sorafenib is indicated for the treatment
of locally recurrent, metastatic, or progressive RAI-
refractory differentiated thyroid cancers. The approval of
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lenvatinib was based on the results of the randomized,
double-blind, multinational, phase 3 SELECT study, in
which lenvatinib significantly improved median
progression-free survival (PFS) and overall response rate
compared with placebo in patients with locally recur-
rent, metastatic, or progressive RAI-refractory differenti-
ated thyroid cancers [2].
Lenvatinib is a multitargeted TKI of vascular endothe-
lial growth factor receptors 1–3 (VEGFRs 1–3), fibro-
blast growth factor receptors 1–4 (FGFRs 1–4), platelet-
derived growth factor receptor α (PDGFR-α), and the
rearranged during transfection (RET) and c-KIT signal-
ing networks, which are implicated in pathogenic angio-
genesis, tumor growth, and cancer progression [3].
Sorafenib significantly prolonged median PFS relative
to placebo in the randomized, double-blind, multi-
national, phase 3 DECISION study [4]. Sorafenib is a
multitargeted TKI of VEGFR 1–3, PDGF-β, c-KIT, FMS-
like tyrosine kinase-3, and RAF kinases [5].
TKIs that block VEGFR, such as lenvatinib or sorafe-
nib, are known to cause delayed healing. Severe compli-
cations of lenvatinib such as bleeding or fistula
formation have been observed in the post-approval
6 months study in Japan [6]. Surgery is not generally
performed in these cases because wound healing is de-
layed when a TKI of VEGFR is being used. TKI has to
be withdrawn preoperatively if surgery needs to be per-
formed. However, when TKI is withdrawn, tumor size
can increase rapidly, and it is dangerous to withdraw it
for a long time. We initiated lenvatinib for a patient with
locally recurrent and metastatic progressive RAI-
refractory differentiated thyroid cancer, and taking lenva-
tinib caused the formation of a giant ulcer in the right
subclavicular lesion.
We report that we encountered a severe case of a sub-
clavicular ulcer caused by lenvatinib and successfully
avoided rupture of the subclavicular artery or vein by
surgically protecting the major vessels with a pectoralis
major musculocutaneous (PMMC) flap.
Case presentation
A 53-year-old woman underwent repeated neck dissec-
tions after undergoing total thyroidectomy and was
given a total of 200 mCi (100 mCi twice) RAI therapy in
an outside hospital. Pathology revealed a papillary car-
cinoma of the tall cell variant. Locoregional recurrence
was not under control; therefore, she visited our hospital
for a second opinion regarding a treatment strategy.
Surgery was performed for locoregional recurrences
three times in our hospital, but it was not under control
and distant metastases were found in the lung and iliac
bone a year later. Therefore, sorafenib was initiated at a
dose of 800 mg daily and was gradually reduced because
of side effects, resulting in a continuous dose of 400 mg.
The locoregional recurrence and distant metastases
progressed 6 months later. We waited for lenvatinib to
be approved in Japan and then administered it.
Before lenvatinib was initiated, computed tomography
(CT) showed a 7-cm mass in the right subclavicular
lesion (Fig. 1A-1, A-2), multiple affected lymph nodes in
the bilateral axilla, and multiple nodules in the lung and
iliac bone. Her thyroglobulin (Tg) was 1663 ng/mL
(Fig. 2), and her thyroid-stimulating hormone was
0.027 μIU/mL.
After lenvatinib was initiated at a dose of 24 mg daily,
her Tg decreased rapidly (Fig. 2). An ulcer occurred in
her right subclavicular lesion at the same time and was
gradually increasing in size (Fig. 3a, b). On day 8, the
lenvatinib was reduced to a dose of 20 mg. The lenvati-
nib was cancelled on day 18 because a pulsation of the
right subclavicular artery was found in the deep portion
of the ulcer. Tg rapidly increased as soon as the lenvati-
nib was cancelled (Fig. 2). Therefore, 10 mg of lenvatinib
was started on day 23. Tg gradually decreased again, but
the size of the ulcer did not change. The patient was at
risk of bleeding from the right subclavicular artery or
vein (Fig. 1B-1, B-2). Therefore, we decided to cover the
ulcer using a PMMC flap.
We considered the following three points in the surgi-
cal approach:
1. Lenvatinib is an antiangiogenic TKI; therefore,
wound healing is delayed. We decided to withdraw it
8 days preoperatively.
2. A large flap was needed to cover the ulcer.
Therefore, we selected a PMMC flap.
3. After the wound was confirmed to be firmly
engrafted, lenvatinib was re-started at a lower dose.
Lenvatinib was preoperatively discontinued for 8 days,
and surgery was performed on day 38 (Fig. 2). The
tumor and clavicle were resected as much as possible
during the surgery. The margin of the ulcer revealed ma-
lignancy on intraoperative pathological examination.
The PMMC flap (7 × 5 cm) was transplanted to the ulcer
(Fig. 3d).
Her postoperative course was uneventful (Fig. 3e). We
confirmed the wound was firmly engrafted and started
8 mg of lenvatinib on day 50 (postoperative day (POD)
12). She was discharged the next day and was followed
as an outpatient. A fistula was found on the posterior
side of the PMMC on day 86 (POD 48) (Fig. 3f ). The
tumor had been reduced by the lenvatinib, and a dis-
charge was coming through the fistula. Therefore, the
lenvatinib was withdrawn. She then developed dyspnea
with right pleural effusion. It was not effective for her to
undergo pleurodesis. She died of respiratory failure by
lung metastases on day 146 (POD 108).
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Fig. 2 A change of thyroglobulin (Tg). The level of Tg is rapidly decreasing when taking lenvatinib
Fig. 1 A-1, A-2 Enhanced CT findings before starting lenvatinib. Tumor is invaded into subcutaneous tissue in the right subclavicular lesion
(arrowhead). B-1, B-2 Enhanced CT findings just before surgery (day 32). A large ulcer occurred in right subclavicular lesion (arrow)
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Discussion
Antiangiogenic TKIs such as lenvatinib or sorafenib can
be used for patients with locally recurrent, metastatic, or
progressive RAI-refractory differentiated thyroid cancers.
Before TKIs, their only option was symptomatic treat-
ments. It is good news that their treatment options have
increased.
Antiangiogenic TKIs such as lenvatinib or sorafenib
are known to have mild side effects such as fatigue, skin
reactions, hypertension, proteinuria, and delayed healing
[7, 8]. However, severe side effects including aerodiges-
tive fistula or bleeding have been reported [9–11].
Therefore, there is a possibility that antiangiogenic TKIs
can cause a patient’s early death. It has not been estab-
lished when they should be started.
The recurrent tumor had infiltrated to the right sub-
clavicular subcutaneous tissue in this case, but lenvatinib
was started because of her strong desire to take it. An
ulcer formed as expected. The size of the tumor was
reduced more than expected, and pulsation of the right
supraclavicular artery was found in the ulcer. There was
a possibility of a rupture from the subclavian artery or
vein in this situation, and it was unsafe to discharge her
from the hospital. Therefore, we decided to perform
surgery.
Surgery is not performed in general for patients taking
TKIs because antiangiogenic TKIs have a side effect of
delayed healing. It was a problem as to how long lenvati-
nib should be withdrawn before and after surgery in this
case. The half-life of lenvatinib is about 30 h [12, 13].
The drug is pharmacologically metabolized during a
period of approximately five times the half-life. There-
fore, most of the lenvatinib should have been metabo-
lized if it was preoperatively withdrawn for more than
7 days. Lenvatinib was preoperatively withdrawn for
8 days in this case. Her postoperative course was
uneventful without any complications. Desai et al. rec-
ommended that the antiangiogenic TKI, sunitinib, used
for the treatment of advanced renal cell carcinoma and
gastrointestinal stromal tumors, should be stopped for a
minimum of 1 week before surgery (which is approxi-
mately four half-lives) and be restarted at least 1 week
after surgery [10].
There is no evidence as to when lenvatinib should be
restarted postoperatively. After confirming, the wound
was engrafted firmly, lenvatinib was restarted on postop-
erative day 12 at a reduced dose of 8 mg. The patient
was discharged the next day.
The wound had been healing well after lenvatinib was
restarted, but fistula formation was found on the poster-
ior side of PMMC flap at POD 48. A dead space
occurred in the subcutaneous lesion because the tumor
was reduced more than expected.
Currently, clinical trials are ongoing in sunitinib and
pazopanib and other antiangiogetic TKIs [14, 15], and
they are expected to be approved in the future. Tumor
reduction can cause serious complications such as bleed-
ing and aerodigestive fistulas in cases of invasion into
large vessels, the trachea, and the esophagus. Therefore,
it is necessary to make the decision to initiate
Fig. 3 Gross findings in the right subclavicular lesion. a Day 5. A small ulcer was found. b Day 13. The size of ulcer was gradually increased. c Day
30. The ulcer had become larger. d Day 38, operation. PMMC flap was transplanted. e Day 50/POD 12. The flap was engrafted well. f Day 68/POD
30. A fistula was found at the posterior side of flap (arrowhead)
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antiangiogenic TKIs carefully. It was reported by Blevins
et al. that antiangiogenic TKIs have caused several cases
of serious aerodigestive fistula formation, especially in
patients undergoing external beam radiation and in
cases with invasion of tumor into the esophagus and
trachea; therefore, special attention should be turned
towards noticing bleeding or fistula formation when
using antiangiogenic TKIs [7]. Once fistula formation
occurs, it is necessary to discontinue TKIs. However,
tumors tend to rapidly grow during the withdrawal of
TKIs. TKIs should be used at a lower dose when
restarting.
There is a possibility that initiating antiangiogenic
TKIs is accelerating the time of death of patients with
locally recurrent, metastatic, or progressive RAI-
refractory differentiated thyroid cancer. Therefore, it is
very important to determine an appropriate time to start
them after considering the patients’ quality of life. How-
ever, there is currently no evidence to support this type
of decision-making. Therefore, we have to continue to
discuss when antiangiogenic TKIs should be initiated.
Conclusions
Fistula formation or bleeding is known to be a severe
side effect of antiangiogenic TKIs such as lenvatinib or
sorafenib. There is a possibility that severe complications
can occur when initiating TKIs in patients whose tumor
has invaded into skin, vessels, trachea, esophagus, and
other areas. Therefore, it is necessary to use antiangio-
genic TKIs very carefully. It is important to determine
the appropriate time to start TKIs; however, there is no
established protocol for this, and it is a problem that
needs urgent attention.
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